SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi

被引:9
|
作者
Meinus, C. [1 ]
Singer, R. [2 ]
Nandi, B. [3 ,4 ]
Jagot, O. [4 ]
Becker-Ziaja, B. [2 ]
Karo, B. [2 ]
Mvula, B. [5 ]
Jansen, A. [2 ]
Baumann, J. [2 ]
Schultz, A. [6 ,7 ]
机构
[1] Charite Univ Med Berlin, Inst Trop Med & Int Hlth, Berlin, Germany
[2] Robert Koch Inst Berlin, Berlin, Germany
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] Kamuzu Cent Hosp Lilongwe, Lilongwe, Malawi
[5] Publ Hlth Inst Malawi, Lilongwe, Malawi
[6] Univ Malawi, Dept Paediat, Coll Med, Lilongwe, Malawi
[7] Univ Bonn, Univ Hosp Bonn, Sect Global Hlth, Bonn, Germany
关键词
COVID-19; prevalence; immunity; Malawi; Africa; COVID-19; PREPAREDNESS;
D O I
10.1016/j.ijid.2021.12.336
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: COVID-19 transmission and disease dynamics in sub-Saharan Africa are not well understood. Our study aims to provide insight into COVID-19 epidemiology in Malawi by estimating SARS-CoV-2 prevalence and immunity after SARS-CoV-2 infection in a hospital-based setting. Methods: We conducted a hospital-based, convenience sampling, cross-sectional survey for SARS-CoV-2 in Lilongwe, Malawi. Participants answered a questionnaire and were tested for SARS-CoV-2 by enzyme linked immunosorbent assay and real-time reverse-transcription polymerase chain reaction (RT-PCR). A surrogate virus neutralization test (sVNT) was performed in seropositive samples to estimate immunity. Poisson regression was used to assess SARS-CoV-2 point prevalence association with demographic and behavioral variables. Findings: The study included 930 participants. We found a combined point prevalence of 10.1%. Separately analyzed, RT-PCR positivity was 2.0%, and seropositivity was 9.3%. Of tested seropositive samples, 90.1% were sVNT positive. We found a high rate (45.7%) of asymptomatic SARS-CoV-2 infection. SARSCoV-2 point prevalence was significantly associated with being a healthcare worker. Interpretation: Our study suggests that official data underestimate COVID-19 transmission. Using sVNTs to estimate immunity in Malawi is feasible and revealed considerable post-infection immunity in our cohort. Subclinical infection and transmission are probably a game-changer in surveillance, mitigation and vaccination strategies. (C) 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
引用
收藏
页码:157 / 165
页数:9
相关论文
共 50 条
  • [21] Mortality in patients with cancer and SARS-CoV-2 infection: Results from the Argentinean Network of Hospital-Based Cancer Registries
    Fattore, Gisel L.
    Olivos, Natalia S. Araoz
    Olalla, Jose E. Carrizo
    Gomez, Lara
    Marucco, Agustina Flamenco
    Mena, Maria Paz Rojas
    [J]. CANCER EPIDEMIOLOGY, 2022, 79
  • [22] Prevalence of SARS-CoV-2 antibodies in hospital employees, Central Germany
    Keller, Christian
    Chung, Ho-Ryun
    Jerrentrup, Andreas
    Feldmann, Leah
    Rohde, Cornelius
    Halwe, Sandro
    Woelfel, Friederike
    Guenther, Susanne
    Renz, Harald
    [J]. JOURNAL OF LABORATORY MEDICINE, 2022, 46 (01) : 61 - 69
  • [23] Prevalence of antibodies to SARS-CoV-2 in Irish hospital healthcare workers
    Allen, Niamh
    Riain, Una Ni
    Conlon, Niall
    Ferenczi, Annamaria
    Carrion Martin, Antonio Isidro
    Domegan, Lisa
    Walsh, Cathal
    Doherty, Lorraine
    O'Farrelly, Cliona
    Higgins, Eibhlin
    Kerr, Colm
    McGrath, Jonathan
    Bergin, Colm
    Fleming, Catherine
    Fitzgerald, Margaret
    de Gascun, Cillian
    Gallagher, Joan
    Igoe, Derval
    Keogan, Mary
    Noonan, Noirin
    Rian, Una Ni
    Smyth, Breda
    Fleming, Catherine
    [J]. EPIDEMIOLOGY AND INFECTION, 2021, 149
  • [24] SARS-CoV-2: Sanitize a hospital
    De Caro, F.
    Moccia, G.
    Borrelli, A.
    Annecchiarico, A.
    Cioffi, G.
    Campanella, A.
    Motta, O.
    Caputo, V.
    Boccia, G.
    Capunzo, M.
    [J]. EUROPEAN JOURNAL OF PUBLIC HEALTH, 2020, 30 : V796 - V796
  • [25] Adaptive immunity against SARS-CoV-2
    Combadiere, Behazine
    [J]. M S-MEDECINE SCIENCES, 2020, 36 (10): : 908 - 913
  • [26] Partial immunity and SARS-CoV-2 mutations
    Hanage, William P.
    Russell, Colin A.
    [J]. SCIENCE, 2021, 372 (6540) : 354 - 354
  • [27] Evolution of antibody immunity to SARS-CoV-2
    Christian Gaebler
    Zijun Wang
    Julio C. C. Lorenzi
    Frauke Muecksch
    Shlomo Finkin
    Minami Tokuyama
    Alice Cho
    Mila Jankovic
    Dennis Schaefer-Babajew
    Thiago Y. Oliveira
    Melissa Cipolla
    Charlotte Viant
    Christopher O. Barnes
    Yaron Bram
    Gaëlle Breton
    Thomas Hägglöf
    Pilar Mendoza
    Arlene Hurley
    Martina Turroja
    Kristie Gordon
    Katrina G. Millard
    Victor Ramos
    Fabian Schmidt
    Yiska Weisblum
    Divya Jha
    Michael Tankelevich
    Gustavo Martinez-Delgado
    Jim Yee
    Roshni Patel
    Juan Dizon
    Cecille Unson-O’Brien
    Irina Shimeliovich
    Davide F. Robbiani
    Zhen Zhao
    Anna Gazumyan
    Robert E. Schwartz
    Theodora Hatziioannou
    Pamela J. Bjorkman
    Saurabh Mehandru
    Paul D. Bieniasz
    Marina Caskey
    Michel C. Nussenzweig
    [J]. Nature, 2021, 591 : 639 - 644
  • [28] Immunity after SARS-CoV-2 infections
    Jagannathan, Prasanna
    Wang, Taia T.
    [J]. NATURE IMMUNOLOGY, 2021, 22 (05) : 539 - 540
  • [29] Toward superhuman SARS-CoV-2 immunity?
    Dennis R. Burton
    Eric J. Topol
    [J]. Nature Medicine, 2021, 27 : 5 - 6
  • [30] SARS-CoV-2 immunity in animal models
    Chen, Zhao
    Yuan, Yaochang
    Hu, Qingtao
    Zhu, Airu
    Chen, Fenghua
    Li, Shu
    Guan, Xin
    Lv, Chao
    Tang, Tian
    He, Yiyun
    Cheng, Jinling
    Zheng, Jie
    Hu, Xiaoyu
    Zhao, Jingxian
    Zhao, Jincun
    Sun, Jing
    [J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2024, 21 (02) : 119 - 133